Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2013-04-12 Annual Report
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
2012年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2012 Annual Report Summary" of 中源协和干细胞生物工程股份公司, which indicates it is a summary of the full annual report. It contains detailed financial data for the year 2012, including assets, liabilities, income, cash flows, shareholder information, management discussion and analysis, business segments, and investment activities. The document is comprehensive and covers the full fiscal year, consistent with an annual report. It is not a brief announcement or a presentation, nor is it a certification or a voting result. The length (15,000 characters) and detailed financial and operational data confirm it is the actual annual report document, not just an announcement or summary notice. Therefore, the correct classification is Annual Report (10-K). FY 2012
2013-04-12 Chinese
2012年年度报告
Annual Report Classification · 100% confidence The document is titled "2012 年年度报告" which translates to "2012 Annual Report". It contains detailed financial data, including income statements, cash flow statements, profit distribution plans, auditor's report mention, management discussion and analysis, company overview, risk factors, and governance information. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. The presence of audited financial statements and comprehensive business analysis confirms it is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2012
2013-04-12 Chinese
关于全资子公司收到政府补助资金的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding a government subsidy received by a wholly-owned subsidiary, including accounting treatment of the subsidy. It is not a full financial report, audit, or management discussion. It is a regulatory announcement about a specific financial event (government grant) affecting the company. The document length is very short (336 characters), and it does not contain detailed financial statements or analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2013-04-07 Chinese
全资子公司和泽生物科技有限公司对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the board of 中源协和干细胞生物工程股份公司 regarding an external investment by its wholly-owned subsidiary 和泽生物科技有限公司. It details the investment overview, the establishment of a joint venture company, the board approval, and the impact on the listed company. The document includes specifics about the investment contracts, shareholder rights, and the strategic rationale. It is not a financial report, earnings release, or regulatory certification. It is a formal announcement of a capital investment transaction involving the company's subsidiary and a joint venture setup. This fits the category of Capital/Financing Update (CAP), as it concerns company fundraising, financing activities, or capital structure changes. The document length is 4402 characters, which is substantive and contains detailed information about the investment, not merely a brief notice or report publication announcement. Therefore, the best classification is CAP with high confidence.
2013-03-18 Chinese
第七届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of the company 中源协和干细胞生物工程股份公司. It details decisions such as approval of an investment by a subsidiary, appointment of a new financial director, and adjustment of senior management remuneration. The document includes voting results and confirms compliance with company law and articles of association. There is no financial data or report content, but rather it is a disclosure of board/management decisions and changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a regulatory filing. Hence, the classification is MANG with high confidence.
2013-03-18 Chinese
关于公司董事、监事、高管减持公司股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the sale of company shares by directors, supervisors, and senior management. It lists specific share transactions by named individuals with their positions and share quantities before and after the transactions. This matches the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives. The document is short and focused solely on insider share transactions, with no financial results or other report content. Therefore, the correct classification is Director's Dealing (DIRS).
2013-02-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.